
According to Benzinga Pro data, during Q4, Veracyte (NASDAQ:VCYT) posted sales of $67.34 million. Earnings were up 25.49%, but Veracyte still reported an overall loss of $10.53 million. In Q3, Veracyte brought in $60.37 million in sales but lost $14.13 million in earnings.